•  
  •  
 

Abstract

BACKGROUND: Acute myocardial infarction (AMI) is a cardiovascular emergency that needs immediate diagnosis and treatment. Myeloperoxidase (MPO) an enzyme generated by active leukocytes, has been connected to atherosclerosis in a mechanistic way and earlier research has suggested that MPO could be employed as a diagnostic and analytical marker for AMI patients. Many cardiovascular disease ( CVD) events have been linked to oxidized-LDL (Ox-LDL) &Glutathione (GSH) . OBJECTIVE: Studies a new, rapidly rising, or cost-effective biomarker for the detection of AMI. PATIENTS AND METHODS: Eighty (80) patients & (40) control offered with chest pain presented to the Coronary Care Unit looking for medical help about their newly developed symptoms. Serum levels were measured by enzyme-linked immunosorbent assay (ELISA).  RESULT: The result of this current study showed that a highly significant association between the serum concentration of MPO and the three groups study (p<0.001). In this present study, a higher significant difference is noted in the level of serum oxLDL in the STEMI group (p < 0.001) and (0.005) in the NSTEMI group. the higher significant difference is noted in the level of serum GSH in NSTEMI & STEMI compared with control (p < 0.001) and between the patents groups (p= 0.019) CONCLUSION : Myeloperoxidase(MPO) & GSH serum level is highly associated with AMI and can be used as                 a biomarker of early diagnosis, progression, and grading of AMI Increased serum concentrations of oxLDL are analytical of future AMI  

DOI

10.52573/ipmj.2021.177175

Download

Share

COinS